Are you looking at GenAI as a creative tool or an operational engine?

In the Life Sciences sector, the conversation around GenAI is often dominated by the "creative" spark, AI generating imagery for patient awareness or drafting social copy. But in an industry defined by precision, focusing solely on the creative output is like admiring the paint job on a car while ignoring the engine.

The Life Sciences industry is also operating in an increasingly active regulatory environment around AI itself. The FDA issued draft guidance in early 2025 explicitly addressing AI use in regulatory submissions, signalling that regulators are actively engaging with how the technology is being deployed across the industry. (See previous post regarding the EU AI Act)

If you want to move the needle in a space where clinical accuracy and regulatory rigour are non-negotiable, you have to stop looking at GenAI as a "content bot" and start treating it as your operational engine.

Strategic Authority: Architecting a Market Entry

In Life Sciences, we aren’t just "running ads." We are architecting market entries. Whether you are launching a new diagnostic tool, a therapeutic, or a biotech platform, the GTM strategy is a complex puzzle of stakeholder mapping, value propositions, and evidence-based messaging.

Strategic authority comes from the ability to synthesise these variables into a cohesive digital feedback loop. When you treat GenAI as an operational layer, you empower your team to move away from the "manual labour" of marketing and toward high-level architecture. You aren't just filling a calendar; you are designing the bridge between scientific innovation and the market that needs it. 

Embedding GenAI into the workflow, rather than just the output, changes the dynamic entirely. Three areas illustrate this most clearly.

The first is precision claims mapping. AI can be configured to cross-reference marketing claims against source clinical data and approved labelling in near real time. Reference verification tools can automatically check that claims are properly supported by cited studies and are consistent with approved labelling, dramatically increasing marketing velocity while maintaining rigorous compliance standards (L7 Creative, 2025).

The second is regulatory pre-screening. Custom models trained on an organisation's approved content and relevant regulatory guidance can flag non-compliant language before it reaches a human reviewer. AI pre-screening tools are starting to shorten review cycles by scanning promotional content before it reaches reviewers, enabling faster time to market and lower costs (CIBER spring, 2025). Pfizer's internal platform, Charlie, illustrates this in practice: the system labels AI-generated content with a risk rating to indicate how much regulatory review it may need, with reused or previously approved language fast-tracked and novel claims flagged for thorough human scrutiny (IntuitionLabs, 2026).

The third is workflow orchestration. McKinsey's benchmarking data shows that leading pharma companies have accelerated their overall submission timelines by up to three times compared with the 2020 industry average, with some now delivering filings eight to twelve weeks after database lock, cutting historical timelines by 50 to 65 per cent. While this data relates to regulatory submissions rather than marketing content specifically, the underlying principle is directly applicable: structured, AI-enabled workflows compress timelines that were previously governed by manual processes.

Why marketers should care about GenAI beyond content

Marketers in Life Sciences sit at the intersection of scientific accuracy, regulatory compliance and commercial performance. That makes GenAI’s operational potential especially relevant. When deployed correctly, GenAI does not just help teams create assets faster. It helps organisations run smarter.

Three shifts are already reshaping how leading companies approach GenAI.

1. Moving from asset creation to workflow optimisation

Most organisations start with creative use cases because they are visible, low risk and easy to pilot. But the real value sits in the operational layer. McKinsey highlights more than 20 high impact use cases across R&D, manufacturing and commercial operations, with many directly affecting marketing workflows. These include automated evidence synthesis, medical review acceleration, content modularisation and compliant personalisation at scale.

For marketers, this means less time spent navigating approval cycles and more time shaping strategy, insight and brand experience.

2. Treating data as a strategic asset, not a by-product

GenAI’s performance depends on the quality, structure and accessibility of the data it draws from. Deloitte’s analysis shows that up to 40 per cent of GenAI’s potential value in Life Sciences sits in R&D and a further 25 to 35 per cent in commercial functions, both of which rely on clean, well governed data.

For marketing teams, this reinforces the need for strong content governance, metadata discipline and clear pathways for AI to access validated scientific information.

3. Rewiring the organisation, not just adding a tool

The organisations realising value are not simply experimenting with GenAI. They are redesigning operating models, governance structures and talent strategies to support it. McKinsey’s survey found that 75 per cent of companies lack a comprehensive GenAI strategy with clear success measures.

For marketers, this is a reminder that GenAI maturity is about embedding AI into the way teams plan, create, review and measure, rather than having the latest model.

What this means for Life Sciences marketers

• Build AI ready content ecosystems: Your content must be structured, traceable and machine readable. This is not just a compliance requirement. It is the foundation for AI driven personalisation, omnichannel orchestration and scientific accuracy.
• Prioritise operational use cases: Look for bottlenecks in your current workflows. Medical review delays, inconsistent claims management, fragmented content libraries and manual evidence gathering are all areas where GenAI can deliver measurable impact.
• Partner across the organisation: Marketing cannot unlock GenAI’s operational value alone. Collaboration with medical, regulatory, IT and data teams is essential. The companies that succeed are those that treat GenAI as a cross functional capability, not a marketing experiment.

How Life Sciences Marketers Can Start Building the Operational Engine

Life Sciences is entering a phase where GenAI will differentiate not by creativity but by operational excellence. Marketers have a pivotal role to play in this shift.

By championing AI ready content, advocating for better data foundations and identifying high value operational use cases, marketing teams can help their organisations move from experimentation to enterprise level impact.

However, understanding the strategic case for operational GenAI is one thing. Knowing where to begin is another. For marketing professionals working within the specific constraints of the Life Sciences sector, the following steps offer a practical path from pilot to embedded capability.

Audit your current workflow before adding any technology

Before evaluating AI tools, map the full journey from brief to published asset. Identify exactly where time is lost, where review cycles are longest, and where errors or compliance queries tend to surface. This baseline is essential: AI should be configured to fix documented friction, not deployed speculatively. Document your SOPs, your approval stages, and the handoff points between commercial, medical, legal, and regulatory teams. Without this map, you cannot measure improvement.

Prioritise the MLR bottleneck as your first operational use case

For most Life Sciences marketing teams, the Medical, Legal, and Regulatory review process is the single greatest constraint on campaign velocity. This is also the area where AI can deliver the clearest, most measurable return.

Begin by implementing AI-assisted pre-screening: tools configured to cross-reference draft content against approved claims libraries and flag language that is likely to require revision before it reaches a human reviewer.

Train AI on your approved content, not generic data

A model trained on publicly available text will not understand your brand's approved claims, your regulatory jurisdiction's specific requirements, or the nuances of your therapeutic area. Invest in building or configuring models that are grounded in your organisation's own validated content.

Pfizer's approach with Charlie, its internal marketing AI platform, is instructive here: the system was deliberately restricted so that all outputs must be grounded in Pfizer's validated content sources, which substantially reduces hallucination risk and keeps outputs within acceptable regulatory parameters.

Establish a risk-tiered content classification system

Not all content carries the same regulatory risk, and your AI workflow should reflect this. Develop a classification framework, whether a simple traffic-light system or a more granular scoring model, that distinguishes between content that reuses previously approved claims (lower risk, faster track), content that adapts existing claims in new contexts (medium risk, standard review), and content that introduces novel assertions requiring full substantiation (higher risk, full MLR cycle). This tiering allows your team to allocate human review time where it is genuinely needed, rather than applying the same level of scrutiny across every asset.

Assign clear ownership of AI outputs within your team structure

One of the most common reasons AI initiatives stall in life sciences marketing is ambiguity about accountability. Designate an AI Product Owner responsible for maintaining the prompts, workflows, and content libraries that the system draws from. Separately, ensure that a qualified reviewer retains clear authority over compliance sign-off. AI can prepare, triage, and pre-screen: it should not be the final decision-maker on regulatory risk. This human-in-the-loop structure is not a limitation of AI; it is the design that makes it deployable within a regulated environment.

Measure the right things from the outset

Too many AI pilots are evaluated on output volume, which tells you very little about operational value. Instead, track time from brief to submission-ready draft, the number of MLR revision cycles per asset, the proportion of content passing first-review without significant amendment, and the time your senior marketers spend on administrative coordination versus strategic work. These metrics will give you a defensible case for investment and a clear signal of where to scale.

Build incrementally, with a clear roadmap to scale.

Johnson and Johnson's experience is a useful reference point: their internal analysis found that 10 to 15 per cent of AI use cases drove 80 per cent of the measurable value. Rather than attempting a broad transformation simultaneously, identify your highest-impact bottleneck, deploy a focused solution, measure the outcome, and use that evidence to justify the next phase.

Life sciences organisations that have successfully moved from pilot to enterprise AI adoption share a consistent characteristic: they resisted the temptation to do everything at once and focused on the architecture.

At Marketing Bytes, that operational architecture is where we focus. Because when the engine is built properly, everything else accelerates with it.